Bruker Corp

Bruker Biosciences Corp. is facing significant challenges due to ongoing cuts in US academic and government funding, which have led to a decline in bookings by high teens percentage for the full year. Management has guided for a mid-single-digit organic revenue decline in Q1 2026 specifically due to this pressure. Despite the company's role in providing high-performance scientific instruments and analytical solutions, these headwinds have negatively impacted its stock performance, making it a detractor in our portfolio this quarter.

Bruker Corp is positioned at a margin inflection point, with a significant portion of its revenues derived from the Life Science end market. The company operates in a duopoly with Thermo Fisher Scientific, focusing on critical instrumentation for pan-omics analysis and spatial biology. Despite current macro challenges, Bruker has diversified its revenue base, with recurring revenues now comprising over one-third of sales. CEO Frank Laukien has indicated a target to return operating margins to the 20% range, with potential for further expansion. The current mid-teens P/E ratio is seen as undervalued compared to historical norms, suggesting significant upside as growth drivers remain intact.

Bruker Corp declined -28.7% during the quarter, ending with a weight of 2.8%. Bruker produces high-performance instruments that enable the exploration of life and materials at a microscopic, molecular, and cellular level. While fourth quarter 2024 results were strong at the high end of guidance, the outlook for 2025 faces challenges from delayed China stimulus and a slow recovery in biopharma. In addition, many of its customers are engaged in early-stage life science research funded by academic and government entities such as the National Institutes of Health, which makes Bruker particularly susceptible to recent government funding cuts at these institutions.

Bruker Corp declined -28.7% during the quarter, ending with a weight of 2.8%. Bruker produces high-performance instruments that enable the exploration of life and materials at a microscopic, molecular, and cellular level. While fourth quarter 2024 results were strong at the high end of guidance, the outlook for 2025 faces challenges from delayed China stimulus and a slow recovery in biopharma. In addition, many of its customers are engaged in early-stage life science research funded by academic and government entities such as the National Institutes of Health, which makes Bruker particularly susceptible to recent government funding cuts at these institutions.

Bruker Corp declined -28.7% during the quarter, ending with a weight of 2.8%. Bruker produces high-performance instruments that enable the exploration of life and materials at a microscopic, molecular, and cellular level. While fourth quarter 2024 results were strong at the high end of guidance, the outlook for 2025 faces challenges from delayed China stimulus and a slow recovery in biopharma. In addition, many of its customers are engaged in early-stage life science research funded by academic and government entities such as the National Institutes of Health, which makes Bruker particularly susceptible to recent government funding cuts at these institutions.

Bruker Corp is positioned at a margin inflection point, with CEO Frank Laukien indicating that operating margins will return to the 20% range from the current 15% in the coming years. The company has diversified its revenue base significantly, with recurring revenues now comprising over 1/3rd of sales. Despite current macro challenges, the top line growth drivers remain intact. The stock trades at a mid-teens P/E, which is low compared to its historical mid-20s range, suggesting significant upside potential as growth resumes. The manager believes that the disconnect between perception and reality creates meaningful upside for Bruker.

Bruker Corp is positioned at a margin inflection point, with a strong presence in the Life Science market and critical instrumentation for applied industrial markets. Despite current macro challenges, Bruker has diversified its revenue base significantly, with recurring revenues now comprising over 1/3rd of sales. CEO Frank Laukien has indicated that operating margins are expected to return to the 20% range, with potential for further expansion. The current mid-teens P/E ratio is seen as undervalued compared to historical norms, especially given the company's growth potential and improved market position.